Patents
Literature
51 results about "Candida auris" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Candida auris is a species of fungus first described in 2009, which grows as yeast. It is one of the few species of the genus Candida which cause candidiasis in humans. Often, candidiasis is acquired in hospitals by patients with weakened immune systems. C. auris can cause invasive candidiasis (fungemia) in which the bloodstream, the central nervous system, and internal organs are infected. It has recently attracted increased attention because of its multiple drug resistance. Treatment is also complicated because it is easily misidentified as other Candida species. C. auris was first described after it was isolated from the ear canal of a 70-year-old Japanese woman at the Tokyo Metropolitan Geriatric Hospital in Japan in 2009. In 2011, South Korea saw its first cases of disease-causing C. auris. Reportedly, this spread across Asia and Europe, and first appeared in the U.S. in 2013. DNA analysis of four distinct but drug-resistant strains of Candida auris indicate an evolutionary divergence taking place at least 4,000 years ago, with a common leap among the four varieties into drug-resistance possibly linked to widespread azole-type antifungal use in agriculture.
Primer probe combination for detecting genital tract pathogenic microorganisms, kit and application
ActiveCN119464524AMicrobiological testing/measurementMicroorganism based processesDiseaseGenital Tract Infections
The invention discloses a primer probe combination and a kit for detecting genital tract pathogenic microorganisms and application. The primer probe combination comprises primer probe sequences as shown in SEQ ID NO.1-SEQ ID NO.96, the genital tract pathogens comprise 27 pathogens capable of causing genital tract diseases, such as ureaplasma parvum, ureaplasma urealyticum, mycoplasma hominis, mycoplasma genitalium, candida albicans, candida glabrata, candida tropicalis, candida auricula, candida krusei and candida duberlin, as well as lactobacillus crispatus, lactobacillus jensenii and lactobacillus gasseri; the lactobacillus lactis comprises four common vaginal lactobacillus lactis, and also comprises a human-derived interior label. On the basis of a fluorescent quantitative PCR technology, the kit can be used for simultaneously detecting 27 pathogens capable of causing genital tract diseases and 4 common lactobacillus vaginalis in an in-vitro sample, not only can cover main pathogens of genital tract infection, but also meets the evaluation on the ecological environment of the vagina, the detection time is shortened to about 40 minutes, and meanwhile, the kit has relatively good specificity and sensitivity.
Owner:ZHEJIANG MOLE BIOTECHNOLOGY CO LTD +1
Heterocyclic pyrimidinedione compound and pesticide and medical application thereof
The invention relates to a heterocyclic pyrimidinedione compound and application thereof in preparation of pesticides and medicines, in particular to the heterocyclic pyrimidinedione compound and application thereof in preparation of herbicides and plant virus resisting agents, and application in preparation of medicines for resisting fungal infection, especially candida auricula infection. The compound provided by the invention has good inhibition effect on KARI enzymes from different sources. Under the dosage of 100g / mu, the weeding effect of the compound provided by the invention on rape during stem and leaf treatment can reach 100%. The compound disclosed by the invention has a good inhibition effect on a candida auricula 12766 strain, and the minimum inhibition concentration (MIC) value of the compound can reach 0.31 mg / L when a YNB culture medium is used. The in-vivo passivation effect of the compound on the tobacco mosaic virus TMV under the concentration of 500 mg / L can reach 64.2%.
Owner:NANKAI UNIV
Application of combination of Cd1 and Mdr1 double-target inhibitor and azole drugs in preparation of antifungal drugs
The invention relates to the technical field of biological medicine, in particular to application of a combination of a Cd1 and Mdr1 double-target inhibitor and an azole drug in preparation of an antifungal drug. Based on the fact that the compound as shown in the formula (I) can be used as a CCd1 and Mdr1 double-target inhibitor, the inhibition effect of the compound on candida albicans, candida auricula, candida glabrata, candida tropicalis, trichophyton rubrum and trichophyton indicus when the compound is combined with azole drugs is further evaluated, and the result shows that the compound as shown in the formula (I) has no obvious antibacterial activity on various fungi, and can be used for preparing a medicine for treating various fungi. The drug resistance of CCd1 and Mdr1 overexpression drug-resistant fungi can be reversed, the activity of Candida albicans, Candida auricula, Candida glabrata, Candida tropicalis, Trichophyton rubrum and Trichophyton indicus can be synergistically inhibited when the drug is combined with azole drugs, the treatment dosage of the azole drugs is effectively reduced, and the drug toxicity is small. Therefore, the compound shown in the formula (I) can improve the antifungal effect of azole drugs and reduce the drug resistance of the azole drugs.
Owner:SHANDONG UNIV
Methods of treatment for Candida auris infections
Disclosed herein are compositions and methods for treating and immunizing against C. auris infection and colonization. The compositions and methods include polypeptides and fragments derived from the C. albicans Als3 protein, homologs thereof, and antibodies or fragments thereof that specifically bind these polypeptides and fragments. Administration of these compositions confers treatment and resistance against C. auris infection and colonization.
Owner:LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT
Application of benzene ring alkoxy substituted sulfonylurea compound in preparation of antifungal drugs
The invention relates to an application of a benzene ring alkoxy substituted sulfonylurea compound in preparation of a medicine for resisting infection caused by fungi, in particular to an application in preparation of a medicine for resisting infection caused by candida auricula. The inhibition constant Ki value of the compound to the candida auricula AHAS can reach 110 nM, and the minimum half inhibition concentration of the compound to the candida auricula can reach 1.2 mu M.
Owner:BAODING NUOWEI TECH CO LTD +1
Use of carbonyl cyanide-4-trifluoromethoxyphenylhydrazone in the prevention and treatment of candida infections
The application discloses the use of carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone in the prevention and treatment of candida infection, belonging to the technical field of candida infection prevention and treatment. Carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone is used as the only active ingredient for preparing a medicine for preventing or treating diseases caused by candida infection, wherein the candida is candida albicans and / or candida auris; or it is used for preparing a bacteriostatic and / or bactericidal product of candida, wherein the candida is candida albicans and / or candida auris. FCCP shows good inhibition of strain growth, good inhibition of biofilm effect and good mitochondria breaking effect in the antibacterial experiments of various candida (wild type candida albicans, drug resistant candida albicans and drug resistant candida auris). Thus, a new treatment drug for candida albicans and candida auris infection is provided.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE +1
Rapid selective detection and monitoring culture medium for candida auricula as well as preparation method and application of rapid selective detection and monitoring culture medium
ActiveCN120624596AMaterial analysis by observing effect on chemical indicatorMicrobiological testing/measurementBiotechnologyRapid identification
The invention discloses a rapid selective detection and monitoring culture medium for candida auricula as well as a preparation method and application of the rapid selective detection and monitoring culture medium, and belongs to the technical field of microbiological detection. The culture medium comprises the following components: peptone, yeast extract powder, glucose, agar, a selective inhibitor, a chromogenic substrate and auxiliary components, the chromogenic substrate comprises the following components: dulcitol and X-Gal, the culture medium disclosed by the invention is added with chloramphenicol and ciclopirox olamine to inhibit infectious microbes, and a chromogenic system of dulcitol and X-Gal realizes specific detection of candida auricula. The culture medium has the advantages of high selectivity, rapid identification and low cost, and is suitable for clinical sample and environment monitoring.
Owner:山东格研生物技术有限公司
A candida auris and its drug-resistant mutation site detection primer probe combination, kit and method
ActiveCN119876449BMicrobiological testing/measurementMicroorganism based processesEchinocandinMicrobiology
This invention discloses a primer-probe combination for detecting Candida auris and its drug-resistant mutation sites. The Candida auris drug-resistant mutation sites include azole resistance mutation sites: mutation sites A395T and A428G in the ERG11 gene, and an anti-echinocandin resistance mutation site: mutation site C1916T in the FKS1 gene. The primer-probe combination includes primer and probe sequences as shown in SEQ ID NO. 1-13, and corresponding kits and detection methods are also provided. In this invention, the primer-probe combination is prepared as a lyophilized reagent, eliminating the need for detection system preparation and directly detecting the nucleic acid extracted from the sample. It features simple operation, good stability, and wide applicability. Furthermore, by detecting the sample, it is possible to quickly determine whether the sample is positive for Candida auris and whether Candida auris drug-resistant mutations have occurred, while also identifying the drug-resistant mutation targets, meeting clinical needs and achieving precision medicine.
Owner:ZHEJIANG UNIV
Highly specific primers and a probe for PCR-based assay for detection of candida auris
Owner:RUTGERS THE STATE UNIV
Crrna for detecting candida auris, combination and use thereof, and method for rapidly detecting candida auris
PCT designated stage expiredWO2025087400A1Microbiological testing/measurementMicroorganism based processesMicrobiologyCandida auris
Provided are a crRNA for detecting Candida auris, a combination and the use thereof, and a method for rapidly detecting Candida auris. A crRNA for detecting Candida auris is designed, which can specifically recognize Candida auris, can guide Cas12a to cleave a target gene, and can specifically detect Candida auris without the need for the isolation and culture of Candida auris in the sample during the detection, thereby distinguishing Candida auris from all other Candida species; such that the specificity of the detection result is improved, and the result is more reliable.
Owner:INST OF PATHOGEN BIOLOGY CHINESE ACADEMY OF MEDICAL SCI
Application of gynostemma pentaphyllum saponin H combined with azole drugs in preparation of antifungal drugs and antifungal drugs
PendingCN122643315AImprove synergistic antibacterial effectAddressing drug resistanceAntifungal drugCandida auris
The application discloses application of gynostemma pentaphyllum saponin H combined with azole drugs in preparation of antifungal drugs and the antifungal drugs, and relates to the technical field of antifungal drugs. It is found through systematic in-vitro drug sensitivity test that natural product gynostemma pentaphyllum saponin H combined with specific azole antifungal drugs (especially posaconazole POS) can produce significant synergistic antifungal effect, especially for clinical thorny aspergillus, candida, new cryptococcus and dark fungi. The combination strategy can significantly reduce the minimum inhibitory concentration of azole drugs, reverse drug resistance, and is effective for multi-drug resistant strains (such as candida auris). The application provides an efficient and low-toxicity new combination drug scheme for overcoming the increasingly serious fungal drug resistance problem.
Owner:JINGZHOU CENT HOSPITAL (JINGZHOU HOSPITAL AFFILIATED TO YANGTZE UNIV)
Use of pyridoxatin and related analogs for control of candida auris
PCT designated stage expiredWO2025050002A1Mutant preparationFungi medical ingredientsChemical synthesisPenicillin
Fungi are prolific producers of secondary metabolites and represent a rich and relatively untapped source for novel drug leads. Numerous successful therapeutics have derived from fungi, including penicillin, cephalosporin, statins, and cyclosporin. However, many promising classes of natural product are never developed into drugs because their chemical synthesis is complex or because the native organisms that naturally produce them, do so at impractically low levels. Pyridoxatins are a class of promising anti-fungal secondary metabolites produced by several naturally occurring strains filamentous fungi. The molecules have complex structures that impede straightforward chemical synthesis or analoging to increase efficacy. The disclosure herein details novel a novel use of pyridoxatin class molecules for the treatment of Candida auris and novel methods for the biosynthesis of pyridoxatins through fermentation of engineered microbes.
Owner:REPETTI PETER P +2
Compositions and systems for disinfection
A disinfectant system, comprising a first aqueous composition having a peracid reactant compound that is either a peroxide compound or an organic acid compound, and a second aqueous composition comprising the peracid reactant compound not selected for the first composition. Each composition is applied separately to, and combined upon, a surface to form a reaction layer, within which a peracid is formed in situ, disinfecting the surface. The compositions can have a flash point, surface tension, and vapor pressure compatible for application as a spray, mist, aerosol, or fog, and can be formulated with an alcohol blend that enables the reaction layer to completely evaporate from the surface after disinfection is complete. In use, the disinfectant systems disclosed herein have up to 99.999% antimicrobial efficacy against organism such as Staphylococcus aureus, Pseudomonasaeruginosa, and Candida auris.
Owner:MARKESBERY BLUE PEARL LLC
Use of larch mushroom acid in the preparation of antifungal drugs
This invention discloses the application of larvicin or its pharmaceutical salt in the preparation of antifungal drugs. The structure of larvicin is shown below. This invention discovers an effective antifungal compound with pharmaceutical potential: larvicin. The compound larvicin of this invention exhibits clear antifungal activity against pathogenic fungi such as *Candida albicans*, *Candida auris*, *Candida tropicalis*, *Candida parapsilosis*, *Candida krusei*, *Cryptococcus neoformans*, *Trichophyton mentagrophytes*, and *Trichophyton rubrum*, with a minimum inhibitory concentration (MIC). 90 The range is 2–8 μg / mL.
Owner:THE NAVAL MEDICAL UNIV OF PLA
Candida auricula B9J08001173 gene overexpression strain, preparation method thereof and application of candida auricula B9J08001173 gene overexpression strain in drug resistance research
The invention relates to a candida auricula B9J08001173 gene overexpression strain, a preparation method thereof and application of the candida auricula B9J08001173 gene overexpression strain in drug resistance research. The Candida auris B9J08001173 gene overexpression strain is preserved in the China General Microbiological Culture Collection Center on February 19, 2025, and the preservation number of the Candida auris B9J08001173 gene overexpression strain is CGMCC (China General Microbiological Culture Collection Center) NO. 33592. The Candida auricula B9J08001173 gene overexpression strain CF1 (OE1173) is constructed for the first time at home and abroad, is an effective model for researching the function of the B9J08001173 gene and the action mechanism of the B9J08001173 gene in the drug resistance of the Candida auricula, can be used for researching the mechanism related to the drug resistance of fluconazole, and has great significance in research and development of related drugs and clinical research and medication guidance.
Owner:HOSPITAL OF DERMATOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES
Candida auricula and drug-resistant mutation site detection primer probe combination, kit and method thereof
ActiveCN119876449AMicrobiological testing/measurementMicroorganism based processesEchinocandinCandida auris
The invention discloses candida auricula and a primer probe combination for detecting drug-resistant mutation sites of the candida auricula. The drug-resistant mutation sites of the candida auricula comprise an anti-azole drug-resistant mutation site, a mutation site A395T and a mutation site A428G of an ERG11 gene and an anti-echinocandin drug-resistant mutation site, namely a mutation site C1916T of an FKS1 gene; the primer probe combination comprises primer and probe sequences as shown in SEQ ID NO. 1-13. The invention also provides a corresponding kit and a detection method. The primer and probe combination is prepared into a freeze-drying reagent, the preparation process of a detection system is omitted during use, nucleic acid extracted from a sample is directly detected, the method has the advantages of being easy and convenient to operate, good in stability and wide in application range, whether the sample is positive of candida auricula or not and whether candida auricula drug-resistant mutation occurs or not can be rapidly determined by detecting the sample, and the detection accuracy is high. Meanwhile, drug-resistant mutation targets can be determined, clinical requirements can be met, and precise medical treatment is achieved.
Owner:ZHEJIANG UNIV
Constant temperature nucleic acid amplification RAA primer probe combination for detecting candida auris and use thereof
PendingUS20250115968A1Microbiological testing/measurementMicroorganism based processesMicroorganismMicrobiology
The present invention discloses a constant temperature nucleic acid amplification RAA primer probe combination for detecting Candida auris and use thereof are provided. The primer probe combination has high amplification efficiency, strong specificity, and no obvious false positive, and can effectively distinguish Candida auris from three closely related bacteria frequently misdiagnosed in a clinical microorganism identification system. Based on an RAA-lateral flow chromatography technology, the present invention establishes a method for rapidly detecting Candida auris can be used for detecting an actual sample after passing the specificity and sensitivity evaluation, and provides a rapid, sensitive, reliable, and effective new method for on-site rapid detection of Candida auris. The method does not need complex instruments, and is particularly suitable for rapid screening and detection of Candida auris in basic laboratories and quarantine sites.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES
Candida auricula B9J08004747 gene overexpression strain, preparation method thereof and application of candida auricula B9J08004747 gene overexpression strain in drug resistance research
The invention relates to a candida auricula B9J08004747 gene overexpression strain, a preparation method thereof and application of the candida auricula B9J08004747 gene overexpression strain in drug resistance research. The Candida auris B9J08004747 gene overexpression strain is preserved in the China General Microbiological Culture Collection Center on December 15, 2025, and the preservation number of the Candida auris B9J08004747 gene overexpression strain is CGMCC (China General Microbiological Culture Collection Center) NO.37013. The Candida auris B9J08004747 gene overexpression The Candida auricula B9J08004747 gene overexpression strain is constructed for the first time at home and abroad, a foundation is laid for the subsequent research on gene functions such as drug resistance of the Candida auricula B9J08004747, and the overexpression strain is named as CF1 (OE4747), is an effective model for researching the drug resistance of the Candida auricula B9J08004747, and has important significance on clinical research and medication guidance.
Owner:HOSPITAL OF DERMATOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES +1
Antifungal quercetin conjugates, methods of preparation and uses thereof
An antifungal compound / conjugate is derived from quercetin, a naturally occurring flavonoid, through a strategic conjugation approach. The resulting quercetin conjugate exhibits enhanced antifungal activity and improved pharmacological properties compared to its parent molecule. The conjugate demonstrates potent efficacy against a range of drug-resistant fungal pathogens, including Candida auris, a critical threat in clinical settings due to its multidrug resistance. The invention also encompasses methods for synthesizing the conjugate, formulating the conjugate in a pharmaceutical preparation, and methods of use for treatment and prevention of superficial and systemic fungal infections.
Owner:UNIV OF JEDDAH
Systems and methods for rapid identification of fungal species using counter-propagating gaussian beam raman spectroscopy and deep learning
Systems and methods for identification of fungal pathogens, including Candida auris and other Candida species, using Raman spectroscopy integrated with machine learning are described. The systems and methods can utilize a counter-propagating Gaussian beam Raman spectroscopy (CPGB-RS) system in combination with a Convolutional Neural Network (CNN) that processes the Raman spectral data to identify and classify fungal species with high accuracy, sensitivity, and specificity.
Owner:WAYNE STATE UNIV
Primer probe combination and kit for digital PCR (polymerase chain reaction) detection of candida auricula and application
PendingCN121992137AMicrobiological testing/measurementMicroorganism based processesMedicineMicrobiology
The invention relates to the field of pathogen detection, in particular to a primer probe combination for digital PCR detection of candida auricula, a kit and application. The primer probe combination provided by the invention is a primer probe combination designed by taking a candida auricula genetic conserved site ITS as a target gene for amplification, can be used for digital PCR detection of candida auricula, can directly perform quantitative detection on candida auricula, can detect the content of candida auricula in a sample to be detected under an extremely low copy number, and has a good application prospect. The Candida auricula loading capacity in an environment sample can be accurately quantified, the method can be suitable for clinical early diagnosis, hospital infection monitoring and basic-level rapid detection, and accurate technical support is provided for prevention and control of multi-drug-resistant Candida auricula.
Owner:BEIJING WEITAIKE BIOTECHNOLOGY CO LTD
Methods of treatment for candida auris infections
Disclosed herein are compositions and methods for treating and immunizing against C. auris infection and colonization. The compositions and methods include polypeptides and fragments derived from the C. albicans Als3 protein, homologs thereof, and antibodies or fragments thereof that specifically bind these polypeptides and fragments. Administration of these compositions confers treatment and resistance against C. auris infection and colonization.
Owner:LOS ANGELES BIOMEDICAL RES INST AT HARBOR UCLA MEDICAL CENT
Candida auris rapid selective detection monitoring culture medium, preparation method and application thereof
ActiveCN120624596BMaterial analysis by observing effect on chemical indicatorMicrobiological testing/measurementBiotechnologyRapid identification
This invention discloses a rapid and selective detection and monitoring culture medium for Candida auris, its preparation method, and its application, belonging to the field of microbial detection technology. The culture medium comprises the following components: peptone, yeast extract, glucose, agar, selectivity inhibitor, chromogenic substrate, and auxiliary components. The chromogenic substrate consists of euonymus alcohol and X-Gal. The culture medium of this invention inhibits contaminating bacteria by adding chloramphenicol and ciclopirox ol, and the chromogenic system of euonymus alcohol and X-Gal achieves specific detection of Candida auris. This culture medium has the advantages of high selectivity, rapid identification, and low cost, and is suitable for clinical samples and environmental monitoring.
Owner:山东格研生物技术有限公司
Use of a dual-target inhibitor of cdr1 and mdr1 in combination with an azole in the preparation of an antifungal drug
The present application relates to the technical field of biological medicine, in particular to the application of Cdr1 and Mdr1 double-target inhibitor combined with azole drugs in the preparation of antifungal drugs. Based on the compound shown in formula (I) can be used as Cdr1 and Mdr1 double-target inhibitor, the inhibitory effect of the compound on Candida albicans, Candida auris, Candida glabrata, Candida tropicalis, Trichophyton rubrum and Trichophyton indiana combined with azole drugs was further evaluated. The results show that the compound shown in formula (I) itself has no obvious antibacterial activity on various fungi, but can reverse the drug resistance of Cdr1 and Mdr1 overexpression drug-resistant fungi. The combination of the compound with azole drugs can synergistically inhibit the activity of Candida albicans, Candida auris, Candida glabrata, Candida tropicalis, Trichophyton rubrum and Trichophyton indiana, effectively reduce the therapeutic dose of azole drugs, and the drug toxicity is small. Therefore, the compound shown in formula (I) can improve the antifungal effect of azole drugs and reduce the drug resistance of azole drugs.
Owner:SHANDONG UNIV
Candida auricula B9J08001173 gene knockout strain, preparation method thereof and effect of Candida auricula B9J08001173 gene knockout strain in drug resistance research
The invention relates to a Candida auricula B9J08001173 gene knockout strain, a preparation method thereof and an effect of the Candida auricula B9J08001173 gene knockout strain in drug resistance research. The Candida auris B9J08001173 gene knockout strain is preserved in the China General Microbiological Culture Collection Center on February 19, 2025, and the preservation number of the Candida auris B9J08001173 gene knockout strain is CGMCC (China General Microbiological Culture Collection Center) NO.33591. The Candida auris B9J08001173 gene knockout strain disclosed by the invention is a Candida The Candida auricula B9J08001173 gene knockout strain CF1 (KO1173) is constructed for the first time at home and abroad, is an effective model for researching the function of the B9J08001173 gene and the action mechanism of the B9J08001173 gene in the drug resistance of the Candida auricula, can be used for researching the mechanism related to the drug resistance of fluconazole, and has great significance in research and development of related drugs and clinical research and medication guidance.
Owner:HOSPITAL OF DERMATOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES
Broad-spectrum antibacterial peptide bsa091 and application thereof
The invention relates to a broad-spectrum antibacterial peptide bsa091 and application thereof, and relates to the technical field of biology. The antibacterial peptide has broad-spectrum antibacterial activity, can inhibit gram-positive bacteria such as staphylococcus aureus, gram-negative bacteria such as escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa, and fungi such as candida auriculata and candida albicans, and has high antibacterial activity. The compound has a relatively strong inhibition effect on clinically separated drug-resistant strains with multiple drug resistance. In addition, the antibacterial peptide is low in hemolytic activity, small in toxicity, short in synthetic sequence, small in molecular weight and easy to chemically synthesize. And the in-vivo safety is ensured while efficient sterilization is realized.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES
Antifungal pharmaceutical composition based on (1, 3)-beta-D-glucan synthase inhibitor
The invention relates to the technical field of biological medicine, in particular to an antifungal pharmaceutical composition based on a (1, 3)-beta-D-glucan synthase inhibitor. In-vitro experiment results show that the antibacterial peptide LL-37 and (1, 3)-beta-D-glucan synthase inhibitors (caspofungin, micafungin, anidulafungin and iremifungin) are combined for use to achieve the effect of synergistically inhibiting candida albicans, candida auricula, candida tropicalis, candida glabrata, candida parapsilosis and candida krusei, so that the antibacterial peptide LL-37 can be combined with the (1, 3)-beta-D-glucan synthase inhibitors (caspofungin, micafungin, anidulafungin and iremifungin) to achieve the effect of inhibiting the (1, 3)-beta-D-glucan synthase inhibitors). And 3) preparing the antifungal drug by combining the 1, 2, 4, 5, 6, 7, 8, 8, 9, 10- However, the antibacterial peptide LL-37 is easily degraded by in-vivo protease, so that the expression of the antibacterial peptide LL-37 in an organism is up-regulated by adopting an antibacterial peptide LL-37 expression accelerant, and the antibacterial peptide LL-37 and a (1, 3)-beta-D-glucan synthetase inhibitor are synergistically antibacterial in the organism.
Owner:SHANDONG UNIV
Candida auricula B9J08001202 gene overexpression strain, preparation method thereof and application of candida auricula B9J08001202 gene overexpression strain in drug resistance research
The invention relates to a candida auricula B9J08001202 gene overexpression strain, a preparation method thereof and application of the candida auricula B9J08001202 gene overexpression strain in drug resistance research. The Candida auris B9J08001202 gene overexpression strain is preserved in the China General Microbiological Culture Collection Center on December 15, 2025, and the preservation number of the Candida auris B9J08001202 gene overexpression strain is CGMCC (China General Microbiological Culture Collection Center) NO.37011. The Candida auris B9J08001202 gene overexpression strain can be The Candida auricula B9J08001202 gene overexpression strain is constructed at home and abroad for the first time, a 6 * His tag protein is introduced to the tail end of the B9J08001202 gene, the foundation is laid for follow-up research on the function of the B9J08001202 gene, and the overexpression strain is named as CF1 (OE1202-His), is an effective model for research on drug resistance of B9J08001202 and has important significance on clinical research and medication guidance.
Owner:HOSPITAL OF DERMATOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES +1
Culture medium for screening and screening method
Provided is a screening medium and a screening method, which can simply and quickly investigate the presence of Candida auris. A screening medium, the screening medium contains an enzyme substrate and is used for screening Candida auris according to the degradation ability of the enzyme substrate, wherein the enzyme substrate contains raffinose and xylose.
Owner:TEIKYO UNIVERSITY
Compounds modified by bensulfuron methyl and application of compounds in preparation of antifungal drugs
The invention relates to a bensulfuron methyl modified compound and application of the bensulfuron methyl modified compound in preparation of drugs for resisting infection caused by fungi, in particular to application of the bensulfuron methyl modified compound in preparation of drugs for resisting infection caused by candida auricula. The inhibition constant Ki value of the compound disclosed by the invention on candida auricula AHAS can reach 0.33 mu M.
Owner:BAODING NUOWEI TECH CO LTD +1